Molecular targeted therapies in metastatic melanoma

Pharmacogenomics and Personalized Medicine

Volumn 6, Issue 1, 2013, Pages 49-56

  Chakraborty, Rima ^a   Wieland, Carilyn N ^b   Comfere, Nneka I ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Braf inhibitors; Metastatic melanoma; Personalized medicine

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DABRAFENIB; DACARBAZINE; DINACICLIB; FLAVOPIRIDOL; IMATINIB; INTERLEUKIN 2; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN MDM2; SORAFENIB; STEM CELL FACTOR RECEPTOR; TRAMETINIB; VEMURAFENIB;

ACRAL MELANOMA; ADVANCED CANCER; AMINO ACID SUBSTITUTION; ARTHRALGIA; BRAF GENE; CANCER RESISTANCE; CDKN2A GENE; CUTANEOUS MELANOMA; DRUG ERUPTION; DRUG FEVER; FATIGUE; GENE MUTATION; HUMAN; KERATOACANTHOMA; KERATOSIS; MELANOMA; METASTATIC MELANOMA; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE C KIT; ONCOGENE N RAS; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHOTOSENSITIVITY; POINT MUTATION; PROGRESSION FREE SURVIVAL; RB1 GENE; REVIEW; SKIN DISEASE; SOMATIC MUTATION; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; UCOSAL MELANOMA;

EID: 84878985402     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: 10.2147/PGPM.S44800     Document Type: Review

References (82)

1. National Cancer Institute. A snapshot of melanoma, 2012. Available from: http://www.cancer.gov/researchandfunding/snapshots/pdf/Melanoma-Snapshots.pdf. Accessed January 16, 2013.
2. National Cancer Institute. SEER Stats Facts sheets. Melanoma of the skin. Available from: http://seer.cancer.gov/statfacts/html/melan.html. Accessed April 16, 2013.
3. Eggermont AM, Schadendorf D. Melanoma and immunotherapy. Hematol Oncol Clin North Am. 2009;23:547-564.
4. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer. 2004;40:1825-1836.
5. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745-2751.
6. Middleton MR, Grobb JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18: 158-166.
7. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105-2116.
8. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med. 2004;351:998-1012.
9. Hodi FS, O'Day SJ, MacDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
10. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364: 2517-2526.
11. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-2465.
12. Dean E, Lorigan P. Advances in the management of melanoma: targeted therapy, immunotherapy and future directions. Expert Rev Anticancer Ther. 2012;12:1437-1448.
13. Midorikawa Y, Tsuji S, Takayama T, Aburatani H. Genomic approach towards personalized anti-cancer drug therapy. Pharmacogenomics. 2012;13:191-199.
14. Awada A, Vandone AM, Aftimos P. Personalized management of patients with solid cancers: moving from patient characteristics to tumor biology. Curr Opin Oncol. 2012;24:297-304.
15. Finn L, Markovic SN, Joseph RW. Therapy for metastatic melanoma: the past, the present and future. BMC Med. 2012;10:23.
16. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
17. Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
18. Goldstein AM, Chan M, Harland M, et al; Lund Melanoma Study Group, Melanoma Genetics Consortium (GenoMEL). Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet. 2007;44:99-106.
19. Meyer LJ, Zone JH. Genetics of cutaneous melanoma. J Invest Dermatol. 1994;103(Suppl 5):112S-116S.
20. Sekulic A, Haluska P Jr, Miller AJ, et al; Melanoma Study Group of Mayo Clinic Cancer Center. Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc. 2008;83:825-846.
21. Gilchrest BA, Eller MS, Geller AC, et al. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med. 1999;340: 1341-1348.
22. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical nevi. Eur J Cancer. 2005;41:28-44.
23. Tannous ZS, Mihm MC Jr, Sober AJ, Duncan LM. Congenital melanocytic nevi: clinical and histopathologic features, risk of melanoma, and clinical management. J Am Acad Dermatol. 2005;52:197-203.
24. Watt AJ, Kotsis SV, Chung KC. Risk of melanoma arising in large congenital melanocytic nevi: a systematic review. Plast Reconstr Surg. 2004;113:1968-1974.
25. Bishop DT, Demenais F, Goldstein AM, et al. Melanoma Genetics Consortium. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst. 2002;94:894-903.
26. Begg CB, Orlow I, Hummer AJ, et al; Genes Environment and Melanoma Study Group. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst. 2005;97:1507-1515.
27. Abdullah C, Wang X, Becker D. Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma. Cell Cycle. 2011;10:977-988.
28. Mann MB, Kaldis P. Cell cycle transitions and Cdk inhibition in melanoma therapy: cyclin' through the options. Cell Cycle. 2011;10:1349.
29. Bennett DC. How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res. 2008;21:27-38.
30. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28:622-629.
31. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A. 1998;95:8292-8297.
32. Shangary S, Wang S. Targeting the MDM-p53 interaction for cancer therapy. Clin Cancer Res. 2008;14:5318-5324.
33. Nikolaou VA, Stratigos AJ, Flaherty KT, Tsao H. Melanoma: new insights and new therapies. J Invest Dermatol. 2012;132:854-863.
34. Al-Mulla F, MacKenzie EM. Differences in in vitro invasive capacity induced by differences in Ki-Ras protein mutations. J Pathol. 2001;195: 549-556.
35. Fecher LA, Amaravadi RK, Flaherty KT. The MAPK pathway in melanoma. Curr Opin Oncol. 2008;20:183-189.
36. Downward J. Targeting RAS signaling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11-22.
37. Houben R, Becker JC, Kappel A, et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog. 2004;3:6.
38. Platz A, Egyhazi S, Ringborg U, Hansson J. Human cutaneous melanoma: a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol. 2008;1: 395-405.
39. Sclafani F, Gullo G, Sheahan K, et al. BRAF mutations in melanoma and colorectal cancer: A single oncogenic mutation with different tumor phenotypes and clinical implications. Crit Rev Oncol Hematol. December 11, 2012.[Epub ahead of print.]
40. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29:1239-1246.
41. Dumaz N, Hayward R, Martin J, et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res. 2006;66:9483-9491.
42. Mooi WJ, Peeper DS. Oncogene-induced cell senescence - halting on the road to cancer. N Engl J Med. 2006;355:1037-1046.
43. Fedorenko IV, Gibney GT, Smalley KS. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene. October 15, 2012.[Epub ahead of print.]
44. Devitt B, Liu W, Salemi R, et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res. 2011;24:666-672.
45. Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012;118: 4014-4023.
46. Ellerhorst JA, Greene VR, Ekmekcioglu S, et al. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res. 2011;17:229-235.
47. Marquette A, André J, Bagot M, Bensussan A, Dumaz N. ERK and PDE4 cooperate to induce RAF isoform switching in melanoma. Nat Struct Mol Biol. 2011;18:584-591.
48. O'Byrne PM, Gauvreau G. Phosphodiesterase-4-inhibition in COPD. Lancet. 2009;374:665-667.
49. Ngkelo A, Adcock IM. New treatments for COPD. Curr Opin Pharmacol. April 18, 2013.[Epub ahead of print.]
50. Crosby T, Fish R, Coles B, Mason MD. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev. 2000;2CD001215.
51. Demunter A, Stas M, Degreef H, De Wolf-Peeters C, van den Oord JJ. Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J Invest Dermatol. 2001;117:1483-1489.
52. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer. 2006;95:581-586.
53. McDermott DF, Sosman JA, et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol. 2008;26:2178-2185.
54. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009;27:2823-2830.
55. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809-819.
56. Chapman P, Hauschild A, Robert C. Updated overall survival (OS) results for BRIM-3, a Phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. J Clin Oncol. 2012;30Suppl:Abstr 8502.
57. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707-714.
58. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010:468:973-977.
59. Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29:3085-3096.
60. Kefford R, Arkenau H, Brown MP, et al. Phase I/II study of dabrafenib, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol. 2010;28Suppl:Abstr 8503.
61. Kirkwood JM, Long GV, Tretzer U, et al. BREAK-MB: a Phase II study assessing overall intracranial response rate to dabrafenib (GSK2118436) in patient with BRAFV600E/K mutation-positive melanoma with brain metastases. J Clin Oncol. 2012;30Suppl:Abstr 8501.
62. Dummer R, Rinderknecht J, Goldinger SM, et al. An open-label pilot study of vemurafenib in previously treated metastastic melanoma patients with brain metastases. J Clin Oncol. 2011;29Suppl:Abstr 8548.
63. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358-365.
64. Chu EY, Wanat KA, Miller CJ, et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol. 2012;67:1265-1272.
65. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366:207-215.
66. Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol. 2012;30: 2375-2383.
67. Trunzer K, Pavlick AC, Schuchter L, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. April 8, 2013.[Epub ahead of print.]
68. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468:968-972.
69. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR. Nature. 2012;483:100-103.
70. Seth R, Crook S, Ibrahem S, et al. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex peturbation of the Ras/Raf signaling pathway in advanced colorectal cancer. Gut. 2009;58: 1234-1241.
71. Baitei EY, Zou M, Al-Mohanna F, et al. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma. J Pathol. 2009;21:707-715.
72. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367: 107-114.
73. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694-1703.
74. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24:4340-4346.
75. Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008;14: 6821-6828.
76. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.
77. Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305:2327-2334.
78. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011;29: 2904-2909.
79. Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008;26:2046-2051.
80. Smalley KS, Eisen TG. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. Int J Cancer. 2003;105:165-175.
81. Niessner H, Beck D, Sinnberg T, et al. The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. J Invest Dermatol. 2011;131: 468-479.
82. Gajewski TF, Salama AKS, Niedzwiecki D, et al. Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). J Transl Med. 2012 Dec 10;10:246.